BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Sunday, April 28, 2024
See today's BioWorld
Home
» Psioxus lands $38.5M for phase I Enad + checkpoint inhibitor combo trial
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Psioxus lands $38.5M for phase I Enad + checkpoint inhibitor combo trial
May 20, 2015
By
Nuala Moran
No Comments
LONDON – Psioxus Ltd. has raised £25 million (US$38.5 million) in a series C round that will enable the company to fund a phase I trial of its oncolytic virus enadenotucirev (Enad) in combination with an immune checkpoint inhibitor.
BioWorld